Due to historic ascertainment bias in the population under study for cancer predisposition, as well as limitations in tumor genomic profiling assay content and design, the frequency and clinical meaning of CHEK2 variation have not been fully defined. This evidence concerns the gene CHEK2 and neoplasm.